AstraZeneca said that its antibody combination Evusheld (tixagevimab co-packaged with cilgavimab) has been authorized by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the prevention of Covid-19 in Britain. Evusheld has been approved to be used in adults who are not presently infected with (or know exposure to) the Covid-19 virus and are […]
AstraZeneca has agreed to supply the US government with up to half a million additional doses of AZD7442, the company’s Covid-19 antibody candidate, for a sum of $205 million. In this connection, AstraZeneca has modified an existing agreement with the US Department of Health and Human Services (HHS) and the US Department of Defense (DoD). […]
AstraZeneca said that AZD7442, which is being developed for the prevention and treatment of Covid-19, will move into two phase 3 clinical trials. AZD7442 is a combination of a couple of monoclonal antibodies (mAbs) extracted from convalescent patients with SARS-CoV-2 infection. It will be assessed in more than 6,000 participants at sites in and outside […]